Attendee search 

Real-time Data Aggregation and analytics in real-time

We support companies gather information and analyze information in real-time speed access to insight facts and evidence into suppliers, vendors. partners and customers

Kitov Pharma (NASDAQ:KTOV) is a clinical stage biopharmaceutical
company advancing first in class oncology therapies. We currently have one FDA
approved drug, Consensi™, and two oncology therapeutic candidates, CM-24 and NT-219:

• CM-24 is a clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with high potential to treat multiple oncology indications. CEACAM1 is associated with angiogenesis, is an
inter-cellular adhesion regulator and acts as a TIM-3 activator. High CEACAM1 expression is known to be associated with poor disease prognosis in a number of tumor types. Thus, blocking CEACAM1 with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms. In a phase I
clinical study, CM-24 demonstrated a good safety profile and promising efficacy signals. We are developing CM-24 in a clinical collaboration with Bristol
Myers-Squibb for Phase 1/2 trial combining CM-24 with nivolumab in NSCLC and pancreatic cancer patients expressing high CEACAM1 levels.

• NT-219 is a first-in-class, dual inhibitor small molecule targeting IRS 1/2 and STAT3, two key signal transducers that promote cancer drug resistance. In preclinical studies, NT-219 demonstrated outstanding
efficacy in preventing acquired resistance and reversing tumor resistance when administered as a monotherapy and in combination with various oncology therapies. We are initiating first-in-man clinical trials with NT219, both as monotherapy and in combination with cetuximab (Erbitux™), with plans to expand combination studies in patients with recurrent or metastatic SCCHN cancer during 2020.

Bio-Tech

MediBase Group is an ITALIAN industrial company that has been operating since 1995 in the field of phytotherapy and medical dietetics; was one of the first companies to deal with Nutraceuticals through the preparation of products addressed exclusively to the health care professionals and distributed through the pharmacies, nursing homes and hospitals.
Titration and standardization are the most important quality criteria in the preparation of MediBase products.
The formulation of our preparations, the choice of active ingredients and their titration are based on accurate studies and analyzes of clinical works, published in the most prestigious international scientific journals, by our R&D.

Investment bank focused on Nordic Life Science companies

Cello Health BioConsulting, previously Defined Health, is a knowledge-based consultancy deeply rooted in science and the unique and ever-evolving challenges and opportunities facing the biopharma industry. We provide strategic advice for corporate growth strategy, disease area selection, indication prioritization, early market access strategy and early value profile development. Cello Health BioConsulting is known for “unconventional insight” – forward thinking, independent,
objective and actionable strategic advice to realize value across all therapeutic areas and stages of
development.

A clinical-stage pharma company with a P2B asset targeted
for multiple psychiatric disorders with unmetmedical needs.
The parent company, Generys Therapeutics Corp.
headquartered in Rep. of Korea is a controlled foreign
company (US IRS code).

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.

We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.